Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
ROSELAND, N.J., May 03, 2017 -- Emisphere Technologies, Inc. (OTCBB:EMIS) announced today that management will host a conference call to discuss the Company's financial and operational results for the first three months ended March 31, 2017, on Friday, May 12, 2017. A press release will be issued prior to market open.
The live webcast of the conference call can be accessed through the Company's web site at www.emisphere.com. The call can also be accessed by dialing (877) 303-9483 (United States and Canada) or (760) 666-3584 (international), and entering Conference ID# 14929495.
In addition, an archive of the webcast can be accessed through the same link and an audio replay of the call will be available beginning Friday, May 12, 2017 at 11:30 AM ET through 11:30 PM ET on May 19, 2017, by calling (855) 859-2056 (United States and Canada) or (404) 537-3406 (International), and entering Conference ID# 14929495.
About Emisphere
Emisphere Technologies is a Drug Delivery Company whose core business strategy is to partner its proprietary drug delivery technology and license Eligen B12. Our thirty year history has made us the established leader in converting injectable therapeutics into advanced oral therapeutics. Utilizing our experience in researching, developing and manufacturing a number of fully characterized carriers in our extensive library, our partners leverage our expertise to employ our unique intracellular delivery mechanism to advance their portfolio and create differentiated line extensions. Our capabilities range from early proof of concept, to extensive development and commercial capabilities.
Emisphere’s technology can enhance the clinical profile of both pre-market and currently marketed products. Further, our broad-based proprietary oral drug delivery platform provides significant increases in bioavailability, facilitates the enhanced absorption of small and large molecules without altering their chemical form, and maintains their biological integrity or pharmacological properties. Finally, it is especially useful for oral delivery of peptides, proteins, oligonucleotides and oligosaccharides. For more information please visit www.emisphere.com.
CONTACT: Alan L. Rubino, CEO 973.532.8000 [email protected]
